Innovation Pharmaceuticals Company Description

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective.

Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19.

The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017.

Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.

Innovation Pharmaceuticals Inc.

Country	United States
Founded	2005
Industry	Biotechnology
Sector	Healthcare
Employees	4
CEO	Leo Ehrlich

Contact Details

Address: 301 Edgewater Place Wakefield, Nevada 01880 United States
Phone	978 921 4125
Website	ipharminc.com

Stock Details

Ticker Symbol	IPIX
Exchange	OTCMKTS
Stock Type	Common Stock
Share Class	Class A Shares
Fiscal Year	July - June
Reporting Currency	USD
ISIN Number	US45782D1000
SIC Code	2836

Key Executives

Name	Position
Leo Ehrlich CPA	Chairman, Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer and Secretary
Jane Harness M.S., MP	Senior Vice President of Clinical Sciences and Portfolio Management
Jim Boeheim	Business Advisor